"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Akero Therapeutics Inc. (NASDAQ:AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced that ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

Hereditary amyloidosis is usually caused by inherited genetic mutations that cause abnormal amyloid proteins to build up and damage different organs in the body. Here’s what you need to know ...

So, amyloidosis, there are several types, several causes, and several symptoms, so you need a comprehensive team to get together and put this puzzle together. Interviewer: Yeah, and we have a clinic ...

Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.

Amyloidosis has “nonspecific” symptoms, meaning they can be the result of many medical conditions and problems, so identifying and diagnosing the disease is difficult. Here are the steps your ...

The symptoms of amyloidosis vary widely due to the many different parts of the body that can be affected by the disease. If amyloid protein accumulates in a single part of the body, the disease is ...

PITTSBURGH (KDKA) -- Amyloidosis is a rare condition that used to almost always be fatal, but doctors are finally making progress in treating it. "I had so many symptoms, and I really didn't think ...

According to the National Organization for Rare Disorders, there are approximately 4,000 new cases of light-chain amyloidosis per year in the U.S. Cardiomyopathy in patients with familial ...

This type of amyloidosis is also progressive but much more slowly. The patient was referred to a cardiothoracic surgeon at Columbia University. Sooner or later, he was going to need a heart ...